EULAR 2019

Rheumatoid Arthritis

Cohort study shows improvement during 25 years of RA treatment

Presented By

Dr Xanthe Matthijssen, Leiden University Medical Center, the Netherlands

Conference

EULAR 2019

4 September, 2019 23:13

Filgotinib in RA patients with inadequate response or naïve to methotrexate

Presented By

Prof. Rene Westhovens, University Hospital Leuven, Belgium

Trial

Phase 3, FINCH-3

Conference

EULAR 2019

4 September, 2019 22:35

Clinical effectiveness of fenebrutinib in RA patients with methotrexate or TNFi failure

Presented By

Dr Stanley Cohen, Metroplex Clinical Research Center, Dallas, USA

Conference

EULAR 2019

4 September, 2019 21:38

Peficitinib likely efficacious and safe

Conference

EULAR 2019

4 September, 2019 20:42

Short methotrexate stop is safe in patients with RA

Presented By

Dr Min Jung Kim, Seoul National University Hospital, South Korea

Conference

EULAR 2019

4 September, 2019 19:47

Tofacitinib is safe according to real-world data analysis

Presented By

Dr Joel Kremer, Albany Medical College, New York, USA

Conference

EULAR 2019

4 September, 2019 18:51

Switching upadacitinib and adalimumab is beneficial in refractory RA

Trial

Phase 3, SELECT-COMPARE

Conference

EULAR 2019

4 September, 2019 17:54

Tapering of prednisone in RA patients who achieved low disease activity or remission with tocilizumab

Presented By

Prof. Gerd Burmester, Free University and Humboldt University of Berlin, Germany

Conference

EULAR 2019

4 September, 2019 16:56

Efficacy and safety of E6011 in RA patients with inadequate response to methotrexate

Presented By

Dr Yoshiya Tanaka, University of Occupational and Environmental Health, Japan

Conference

EULAR 2019

4 September, 2019 15:58

Preliminary efficacy and safety data of RG6125 in RA patients with an inadequate response to TNF inhibitors

Presented By

Uwe Junker, Roche Innovation Center Basel, Switzerland

Conference

EULAR 2019

4 September, 2019 14:01

Integrated 10-year analysis confirms safety profile abatacept

Presented By

Dr Teresa Simon, Bristol-Myers Squibb, USA

Trial

Cohort study, ARTIS, RABBIT, FORWARD, British Columbia Canadian RA Cohort

Conference

EULAR 2019

4 September, 2019 13:03

Switching among multiple infliximab biosimilars does not cause immunogenicity

Presented By

Dr Jéróme Avouac, Paris Descartes University, France

Conference

EULAR 2019

4 September, 2019 12:06

Switch to sarilumab from adalimumab is efficacious and safe

Presented By

Dr Gerd Burmester, Free University and Humboldt University of Berlin, Germany

Trial

MONARCH

Conference

EULAR 2019

4 September, 2019 10:07

Axial Spondyloarthritis

Psoriatic Arthritis

Efficacy and safety of ixekizumab versus adalimumab in patients with PsA

Presented By

Dr Roy Fleischmann, University of Texas Southwestern Medical Center, Dallas, USA

Conference

EULAR 2019

4 September, 2019 11:20

Efficacy and safety of bimekizumab in patients with active PsA

Presented By

Dr Christopher Ritchlin, University of Rochester Medical Centre, USA

Trial

Phase 2, BE ACTIVE

Conference

EULAR 2019

4 September, 2019 11:10

Filgotinib is efficacious and safe in PsA

Presented By

Prof. Philip Mease, Swedish Medical Center and University of Washington, Seattle, USA

Trial

Phase 2, EQUATOR

Conference

EULAR 2019

4 September, 2019 11:00

Ixekizumab improves signs and symptoms in TNFi-naïve PsA patients

Presented By

Dr Amanda Gellett, Eli Lilly, USA

Trial

Phase 3, SPIRIT-P2

Conference

EULAR 2019

4 September, 2019 10:50

Etanercept and methotrexate as first-line treatment in PsA

Presented By

Prof. Philip Mease, University of Washington, USA

Trial

Phase 3, SEAM-PsA

Conference

EULAR 2019

4 September, 2019 10:40

Unacceptable pain is common in patients with psoriatic arthritis

Presented By

Dr Tor Olofsson, Lund University, Sweden

Conference

EULAR 2019

4 September, 2019 10:33

Osteoarthritis and Osteoporosis

Miscellaneous